Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

124.33 +5.49 (+4.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Abivax SA - American Depositary Shares

< Previous 1 2 3 Next >
News headline image
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
From Abivax
Via GlobeNewswire
News headline image
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Closing of $920 Million Public Offering
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
From Abivax
Via GlobeNewswire
News headline image
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
From Abivax
Via GlobeNewswire
News headline image
Abivax announces trading resumption of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
From Abivax
Via GlobeNewswire
News headline image
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Launch of Public Offering of American Depositary Shares
From Abivax
Via GlobeNewswire
News headline image
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
From Abivax
Via GlobeNewswire
News headline image
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Results of its May 11, 2026 Annual General Meeting
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
From Abivax
Via GlobeNewswire
News headline image
Abivax to Present Data on Obefazimod at Digestive Disease Week®
From Abivax
Via GlobeNewswire
News headline image
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
From Abivax
Via GlobeNewswire
News headline image
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
From Abivax
Via GlobeNewswire
News headline image
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
From Abivax
Via GlobeNewswire
News headline image
Abivax Provides 2026 Corporate Outlook
From Abivax
Via GlobeNewswire
News headline image
Abivax to be Added to Nasdaq Biotechnology Index
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
From Abivax
Via GlobeNewswire
News headline image
Abivax Presents Third Quarter 2025 Financial Results
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
From Abivax
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.